Moran Wealth Management LLC Has $29.23 Million Stake in Zoetis Inc. $ZTS

Moran Wealth Management LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 22.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 247,304 shares of the company’s stock after purchasing an additional 44,563 shares during the quarter. Zoetis accounts for 0.9% of Moran Wealth Management LLC’s portfolio, making the stock its 14th largest position. Moran Wealth Management LLC’s holdings in Zoetis were worth $29,234,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Counterpoint Mutual Funds LLC purchased a new position in Zoetis during the first quarter valued at approximately $5,058,000. Investors Asset Management of Georgia Inc. GA ADV lifted its position in Zoetis by 8.6% in the 1st quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 6,212 shares of the company’s stock worth $734,000 after buying an additional 491 shares in the last quarter. Leelyn Smith LLC lifted its position in Zoetis by 12.5% in the 1st quarter. Leelyn Smith LLC now owns 31,522 shares of the company’s stock worth $3,726,000 after buying an additional 3,501 shares in the last quarter. World Investment Advisors boosted its stake in shares of Zoetis by 43.8% during the 1st quarter. World Investment Advisors now owns 42,736 shares of the company’s stock valued at $5,052,000 after buying an additional 13,022 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Zoetis during the 1st quarter valued at $1,872,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This represents a 44.91% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael B. Mccallister bought 3,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Stock Down 0.1%

ZTS opened at $74.73 on Friday. The business has a 50 day moving average price of $84.04 and a 200 day moving average price of $109.40. Zoetis Inc. has a twelve month low of $71.47 and a twelve month high of $161.77. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The firm has a market cap of $31.33 billion, a P/E ratio of 12.39, a price-to-earnings-growth ratio of 1.17 and a beta of 0.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter last year, the business earned $1.48 EPS. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts forecast that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is currently 35.16%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ZTS shares. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Stifel Nicolaus reduced their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research report on Friday, June 26th. UBS Group lowered their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Barclays cut their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $126.92.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
• Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc (NYSE:ZTS) Dividend Quality Draws Focus
• Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors…
• Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action…

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.